Last updated on May 2018

A Study of LY3202626 on Disease Progression in Participants With Mild Alzheimer's Disease Dementia


Brief description of study

The main purpose of this study is to evaluate the safety and the effect on brain tau of the study drug LY3202626 in participants with mild Alzheimer's disease (AD) dementia.

Clinical Study Identifier: NCT02791191

Contact Investigators or Research Sites near you

Start Over

Elly Lee

Irvine Clinical Research Center
Irvine, CA United States

Shawn Kile

Sutter Medical Group
Sacramento, CA United States

Stephen Thein

Pacific Research Network Inc
San Diego, CA United States

MICHAEL PLOPPER

Sharp Mesa Vista Hospital
San Diego, CA United States

Alireza Atri

Ray Dolby Brain Health Center/Sutter Health/CPMC
San Francisco, CA United States

John Duffy

Syrentis Clinical Research
Santa Ana, CA United States

United States

North Bay Neuroscience Institute
Sebastopol, CA United States

Peter McAllister

New England Institute for Clinical Research
Stamford, CT United States

James Ellison

Christiana Care Health Service
Wilmington, DE United States

Nandita Jones

Clinical Neuroscience Solutions Inc
Jacksonville, FL United States

Scott Franczek

Compass Research
Melbourne, FL United States

Elena Valor

Florida International Research Center
Miami, FL United States

Francisco Miranda

New Horizon Research Center
Miami, FL United States

Brad Herskowitz

The Neurology Research Group, LLC
Miami, FL United States

Vikram Atit

Suncoast Clinical Research
New Port Richey, FL United States

John Nardandrea

Renstar Medical Research
Ocala, FL United States

Kelly Taylor

Sensible Healthcare
Ocoee, FL United States

SUSAN STEEN

Axiom Research
Tampa, FL United States

Christopher Recknor

United Osteoporosis Center
Gainesville, GA United States

James Stevens

Fort Wayne Neurological Center
Fort Wayne, IN United States

Martin Farlow

Indiana University School of Medicine
Indianapolis, IN United States

Scott Teeter

Cotton O'Neil Clinic
Topeka, KS United States

Dwight St Clair

Heartland Research Associates
Wichita, KS United States

Paul Rosenberg

Johns Hopkins University School of Medicine
Baltimore, MD United States

Paul Solomon

Boston Center for Memory
Newton, MA United States

Curtis Schreiber

Missouri Memory Center
Bolivar, MO United States

Siddharth Kaul

Clinical Research Professionals
Chesterfield, MO United States

Franco Sicuro

Millenium Psychiatric Associates LLC
Creve Coeur, MO United States

Stanley Fisher

St Lukes Hospital
Kansas City, MO United States

JOHN MORRIS

Washington University School of Medicine
Saint Louis, MO United States

Bharat Mocherla

Las Vegas Medical Research
Las Vegas, NV United States

Mark Ornstein

Memory Enhancement Center of America, Inc.
Eatontown, NJ United States

Jeffrey Greenberg

Pyramid Clinical Research
Monroe, NJ United States

Sanjiv Sharma

Advanced Memory Research Institute of New Jersey
Toms River, NJ United States

Ashok Patel

Bio Behavioral Health
Toms River, NJ United States

David Hart

Albany Medical College
Albany, NY United States

Horace Capote

Dent Neurological Institute
Amherst, NY United States

Meenakshi Patel

Valley Medical Primary Care
Centerville, OH United States

Joel Vandersluis

Neurology Diagnostics, Inc.
Dayton, OH United States

Deborah Gould

Insight Clinical Trials
Shaker Heights, OH United States

David Weisman

Abington Neurological Associates
Abington, PA United States

Paul Gross

Lehigh Center for Clinical Research
Allentown, PA United States

Marvin Kalafer

Clinical Trial Center, LLC, Psychiatry
Jenkintown, PA United States

David Stickler

Clinical Trials of South Carolina
Charleston, SC United States

Claudia Padilla

Baylor AT&T Memory Center
Dallas, TX United States

Bryan Spann

Nantz National Alzheimer Center
Houston, TX United States

Paul Schulz

University of Texas Health Services Center - Houston
Houston, TX United States

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Box Hill, Australia

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Chermside, Australia

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Darlinghurst, Australia

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Erina, Australia

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Glen Iris, Australia

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Heidelberg, Australia

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Herston, Australia

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Nedlands, Australia

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Parkville, Australia

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
West Perth, Australia

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Gatineau, Canada

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Ottawa, Canada

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Verdun, Canada

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Akashi, Japan

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Hachioji, Japan

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Ikeda, Japan

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Kasukabe-shi, Japan

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Kyoto, Japan

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Nagoya, Japan

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Nerima-ku, Japan

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Osaka, Japan

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Setagaya-ku, Japan

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Takamatsu, Japan

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Tokyo, Japan

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Wako, Japan

Eli Lilly and Company

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Yokosuka-shi, Japan

Lawrence Goldstick

University of Cincinnati Health Neurology
Dayton, OH United States

James Andersen

Meridien Research
Spring Hill, FL United States